These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 12439929)
1. Detection of soluble TRAIL in HBV infected patients and its clinical implications. Han LH; Sun WS; Ma CH; Zhang LN; Liu SX; Zhang Q; Gao LF; Chen YH World J Gastroenterol; 2002 Dec; 8(6):1077-80. PubMed ID: 12439929 [TBL] [Abstract][Full Text] [Related]
2. [Soluble tumor necrosis factor related apoptosis inducing ligand (sTRAIL) and clinical outcome of HBV infection in human]. Yue FE; Liu DY; Song J; Zhang LN Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2005 Jun; 19(2):146-8. PubMed ID: 16027782 [TBL] [Abstract][Full Text] [Related]
3. Natural history of chronic hepatitis B REVEALed. Chen CJ; Yang HI J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729 [TBL] [Abstract][Full Text] [Related]
4. Soluble human leukocyte antigen-G expression in hepatitis B virus infection and hepatocellular carcinoma. Park Y; Park Y; Lim HS; Kim YS; Hong DJ; Kim HS Tissue Antigens; 2012 Feb; 79(2):97-103. PubMed ID: 22136460 [TBL] [Abstract][Full Text] [Related]
5. Hepatitis B surface antigen-negative, but HBV DNA-positive patients in Bangladesh. Mahtab MA; Akbar SM; Rahman S Bangladesh Med Res Counc Bull; 2012 Dec; 38(3):104-7. PubMed ID: 23540186 [TBL] [Abstract][Full Text] [Related]
6. Serum soluble death receptor 5 concentration in patients with chronic hepatitis B is associated with liver damage and viral antigen level. Du J; Wang L; Han J; Gao L; Ma C; Liang X Clin Biochem; 2012 Jul; 45(10-11):845-7. PubMed ID: 22537456 [TBL] [Abstract][Full Text] [Related]
7. Soluble fibrinogen-like protein 2 levels in patients with hepatitis B virus-related liver diseases. Van Tong H; Van Ba N; Hoan NX; Binh MT; Quyen DT; Son HA; Van Luong H; Quyet D; Meyer CG; Song LH; Toan NL; Velavan TP BMC Infect Dis; 2018 Nov; 18(1):553. PubMed ID: 30419833 [TBL] [Abstract][Full Text] [Related]
8. Biochemical, virological, immunological and histopathological features of 702 incidentally detected chronic hepatitis B virus carriers in Bangladesh. Al-Mahtab M; Akbar SM; Rahman S; Kamal M; Khan MS Digestion; 2012; 86(1):1-5. PubMed ID: 22688441 [TBL] [Abstract][Full Text] [Related]
9. Natural History of Chronic Hepatitis B Virus Infection in Ahvaz City, Iran. Makvandi M; Soleimani Jelodar R; Samarbafzadeh A; Neisi N; Sharifi Z; Gholampour A; Masjedizadeh A; Shayesteh A Asian Pac J Cancer Prev; 2018 Aug; 19(8):2125-2129. PubMed ID: 30139211 [TBL] [Abstract][Full Text] [Related]
10. The prognosis and management of inactive HBV carriers. Invernizzi F; ViganĂ² M; Grossi G; Lampertico P Liver Int; 2016 Jan; 36 Suppl 1():100-4. PubMed ID: 26725905 [TBL] [Abstract][Full Text] [Related]
12. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Chen JD; Yang HI; Iloeje UH; You SL; Lu SN; Wang LY; Su J; Sun CA; Liaw YF; Chen CJ; Gastroenterology; 2010 May; 138(5):1747-54. PubMed ID: 20114048 [TBL] [Abstract][Full Text] [Related]
13. Viral level is an indicator of long-term outcome of hepatitis B virus e antigen-negative carriers with persistently normal serum alanine aminotransferase levels. Nakazawa T; Shibuya A; Takeuchi A; Shibata Y; Hidaka H; Okuwaki Y; Takada J; Tanaka Y; Watanabe M; Minamino T; Sakurai K; Koizumi W J Viral Hepat; 2011 Jul; 18(7):e191-9. PubMed ID: 21692932 [TBL] [Abstract][Full Text] [Related]
14. Significant differences in serum activities of matrix metalloproteinase-2 and -9 between HCV- and HBV-infected patients and carriers. Kuo WH; Chou FP; Lu SC; Chu SC; Hsieh YS Clin Chim Acta; 2000 Apr; 294(1-2):157-68. PubMed ID: 10727681 [TBL] [Abstract][Full Text] [Related]
15. [Hepatitis B virus genotypes and alanine aminotransferase levels in HBeAg negative patients with chronic hepatitis B and liver cirrhosis]. Li JQ; Zhuang H; Du H; Wang XH; Duan XZ Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):491-3. PubMed ID: 16042881 [TBL] [Abstract][Full Text] [Related]
16. Association between TRAIL expression on peripheral blood lymphocytes and liver damage in chronic hepatitis B. Chen GY; He JQ; Lu GC; Li MW; Xu CH; Fan WW; Zhou C; Chen Z World J Gastroenterol; 2005 Jul; 11(26):4090-3. PubMed ID: 15996036 [TBL] [Abstract][Full Text] [Related]
17. NIH consensus development statement on management of hepatitis B. Belongia EA; Costa J; Gareen IF; Grem JL; Inadomi JM; Kern ER; McHugh JA; Petersen GM; Rein MF; Sorrell MF; Strader DB; Trotter HT NIH Consens State Sci Statements; 2008 Oct 22-24; 25(2):1-29. PubMed ID: 18949020 [TBL] [Abstract][Full Text] [Related]
18. Comparison of genotypes C and D of the hepatitis B virus in Japan: a clinical and molecular biological study. Duong TN; Horiike N; Michitaka K; Yan C; Mizokami M; Tanaka Y; Jyoko K; Yamamoto K; Miyaoka H; Yamashita Y; Ohno N; Onji M J Med Virol; 2004 Apr; 72(4):551-7. PubMed ID: 14981757 [TBL] [Abstract][Full Text] [Related]
19. Variations in the serum concentrations of soluble Fas and soluble Fas ligand in Vietnamese patients infected with hepatitis B virus. Song le H; Binh VQ; Duy DN; Bock TC; Kremsner PG; Luty AJ; Mavoungou E J Med Virol; 2004 Jun; 73(2):244-9. PubMed ID: 15122799 [TBL] [Abstract][Full Text] [Related]
20. Promoting effect of hepatitis B virus on the expressoin of phospholipase A2 group IIA. Zhu C; Song H; Shen B; Wu L; Liu F; Liu X Lipids Health Dis; 2017 Jan; 16(1):5. PubMed ID: 28077172 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]